JPWO2020077257A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020077257A5 JPWO2020077257A5 JP2021519705A JP2021519705A JPWO2020077257A5 JP WO2020077257 A5 JPWO2020077257 A5 JP WO2020077257A5 JP 2021519705 A JP2021519705 A JP 2021519705A JP 2021519705 A JP2021519705 A JP 2021519705A JP WO2020077257 A5 JPWO2020077257 A5 JP WO2020077257A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- amino acid
- acid sequence
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 72
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 70
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 51
- 229920001184 polypeptide Polymers 0.000 claims description 50
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 50
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 33
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 210000002865 immune cell Anatomy 0.000 claims description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 239000002458 cell surface marker Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000003675 cytokine receptors Human genes 0.000 claims description 2
- 108010057085 cytokine receptors Proteins 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 5
- 230000003213 activating effect Effects 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Description
PD-1に特異的に結合するポリペプチド(以下、PD-1結合ポリペプチドとも呼ばれる)が本明細書に提供される。いくつかの実施形態では、提供される結合ポリペプチドは、PD-1に結合する少なくとも1つのVHHドメインを含む。いくつかの実施形態では、本明細書に提供されるPD-1結合ポリペプチドは、各々がPD-1に個々に結合する1、2、3、4、5、6、7、または8個のVHHドメインを含む。いくつかの実施形態では、本明細書に提供されるPD-1結合ポリペプチドは、PD-1に結合する1、2、3、または4個のVHHドメインを含む。いくつかの実施形態では、PD-1結合ポリペプチドは、単一特異性である。いくつかの実施形態では、PD-1結合ポリペプチドは、多重特異性である。例えば、提供されるPD-1結合ポリペプチドは、PD-1に結合する少なくとも1つのVHHドメインと、PD-1以外の1つ以上の標的タンパク質に結合する1つ以上の追加のVHHドメインなどの1つ以上の追加の結合ドメインとを含んでもよいポリペプチドを含む。
特定の実施形態では、例えば以下の項目が提供される。
(項目1)
PD-1に特異的に結合する少なくとも1つの重鎖のみの可変ドメイン(PD-1 VHHドメイン)を含む、PD-1結合ポリペプチド構築物。
(項目2)
PD-1に特異的に結合する少なくとも1つの重鎖のみの可変ドメイン(PD-1 VHHドメイン)と、PD-1以外の標的に結合する1つ以上の追加の結合ドメインと、を含む、PD-1結合ポリペプチド構築物。
(項目3)
前記少なくとも1つのVHHドメインが、配列番号268、272、273、および313からなる群から選択されるアミノ酸配列を含む相補性決定領域1(CDR1)と、配列番号278または314に記載されるアミノ酸配列を含む相補性決定領域2(CDR2)と、配列番号283または315に記載されるアミノ酸配列を含む相補性決定領域3(CDR3)と、を含む、項目1に記載のPD-1結合ポリペプチド構築物。
(項目4)
配列番号268、272、273、および313からなる群から選択されるアミノ酸配列を含む相補性決定領域1(CDR1)と、配列番号278または314に記載されるアミノ酸配列を含む相補性決定領域2(CDR2)と、配列番号283または315に記載される選択されたアミノ酸配列を含む相補性決定領域3(CDR3)と、を含む、少なくとも1つの重鎖のみの可変ドメイン(PD-1 VHHドメイン)を含む、PD-1結合構築物。
(項目5)
PD-1に特異的に結合する前記PD-1 VHHドメインが、PD-1とPD-L1との相互作用を遮断する、項目1、2、3、または4のいずれかに記載のPD-1結合ポリペプチド構築物。
(項目6)
前記1つ以上の追加の結合ドメインが、共刺激分子に結合する、項目2に記載のPD-1結合ポリペプチド構築物。
(項目7)
前記1つ以上の追加の結合ドメインが、T細胞表面マーカーに結合する、項目2に記載のPD-1結合ポリペプチド構築物。
(項目8)
前記T細胞表面マーカーが、CD8である、項目7に記載のPD-1結合ポリペプチド構築物。
(項目9)
前記T細胞表面マーカーが、CD4である、項目7に記載のPD-1結合ポリペプチド構築物。
(項目10)
前記1つ以上の追加の結合ドメインが、PD1以外の免疫チェックポイントに結合する、項目2に記載のPD-1結合ポリペプチド構築物。
(項目11)
前記1つ以上の追加の結合ドメインが、免疫細胞上の活性化受容体に結合する、項目2に記載のPD-1結合ポリペプチド構築物。
(項目12)
前記1つ以上の追加のドメインが、腫瘍関連抗原(TAA)に結合する、項目2に記載のPD-1結合ポリペプチド構築物。
(項目13)
前記1つ以上の追加の結合ドメインが、サイトカイン受容体に結合する、項目2に記載のPD-1結合ポリペプチド構築物。
(項目14)
前記ポリペプチドが、免疫グロブリンFc領域を含む、項目1、2、3、または4のいずれかに記載のPD-1結合ポリペプチド構築物。
(項目15)
前記少なくとも1つのPD-1 VHHドメインが、配列番号251~267、284、もしくは312のいずれかに記載される配列、または配列番号251~267、284、もしくは312のいずれかと少なくとも85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、もしくは99%の配列同一性を示すアミノ酸の配列を含み、PD-1に結合する、項目1、2、3、または4のいずれかに記載のPD-1結合ポリペプチド構築物。
(項目16)
前記少なくとも1つのPD-1 VHHドメインが、それぞれ配列番号268、278、および283、それぞれ配列番号272、278、および283、またはそれぞれ配列番号273、278、および283に記載されるCDR1、CDR2、およびCDR3を含む、項目1または2に記載のPD-1結合ポリペプチド構築物。
(項目17)
配列番号268、272、273、および313からなる群から選択されるアミノ酸配列を含む相補性決定領域1(CDR1)と、配列番号278または314に記載されるアミノ酸配列を含む相補性決定領域2(CDR2)と、配列番号283または315に記載されるアミノ酸配列を含む相補性決定領域3(CDR3)と、を含む、PD-1に結合する単離された単一ドメイン抗体。
(項目18)
配列番号251~267もしくは284のいずれかに記載されるアミノ酸配列、または配列番号251~267、284、もしくは312のいずれかと少なくとも85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、もしくは99%の配列同一性を示すアミノ酸の配列を含み、PD-1に結合する、項目17に記載の単離された単一ドメイン抗体。
(項目19)
前記sdAbが、配列番号251、252、253、254、255、256、257、258、259、260、261、262、263、264、265、266、267、284、または312に記載されるアミノ酸の配列を含む、項目18に記載の単離された単一ドメイン抗体。
(項目20)
項目1~4のいずれかに記載のPD-1結合ポリペプチドをコードする、ポリヌクレオチド(複数可)。
(項目21)
項目17~19のいずれかに記載の単一ドメイン抗体をコードする、ポリヌクレオチド(複数可)。
(項目22)
項目20または21に記載のポリヌクレオチドを含む、ベクター。
(項目23)
項目20もしくは21に記載のポリヌクレオチド(複数可)、または項目22に記載のベクターを含む、細胞。
(項目24)
ポリペプチドを産生する方法であって、細胞に、項目20もしくは21に記載のポリヌクレオチド(複数可)、または項目22に記載のベクターを導入することと、前記ポリペプチド構築物を産生するための条件下で前記細胞を培養することと、を含む、方法。
(項目25)
項目1~4のいずれかに記載の結合分子または項目17~19のいずれかに記載の単一ドメイン抗体を含む結合分子を含む、操作された免疫細胞であって、任意選択的に、前記結合分子が、前記細胞から分泌可能である、操作された免疫細胞。
(項目26)
項目1~4のいずれかに記載のPD-1結合ポリペプチド、項目17~19のいずれかに記載の単一ドメイン抗体、または項目25に記載の操作された免疫細胞を含む、医薬組成物。
(項目27)
対象における免疫応答を刺激または誘発する方法であって、それを必要とする対象に、項目1~4のいずれかに記載のPD-1結合ポリペプチド、項目17~19のいずれかに記載の単一ドメイン抗体、または項目25に記載の操作された免疫細胞、または項目26に記載の医薬組成物を投与することを含む、方法。
(項目28)
対象における疾患または状態を治療する方法であって、それを必要とする対象に、治療有効量の項目1~4のいずれかに記載のPD-1結合ポリペプチド、項目17~19のいずれかに記載の単一ドメイン抗体、または項目25に記載の操作された免疫細胞、または項目26に記載の医薬組成物を投与することを含む、方法。
Provided herein are polypeptides that specifically bind to PD-1 (hereinafter also referred to as PD-1 binding polypeptides). In some embodiments, provided binding polypeptides comprise at least one VHH domain that binds to PD-1. In some embodiments, the PD-1 binding polypeptides provided herein comprise 1, 2, 3, 4, 5, 6, 7, or 8 molecules that each individually bind to PD-1. Contains VHH domains. In some embodiments, the PD-1 binding polypeptides provided herein comprise 1, 2, 3, or 4 VHH domains that bind PD-1. In some embodiments, the PD-1 binding polypeptide is monospecific. In some embodiments, the PD-1 binding polypeptides are multispecific. For example, provided PD-1 binding polypeptides can have at least one VHH domain that binds PD-1 and one or more additional VHH domains that bind one or more target proteins other than PD-1. It includes polypeptides that may include one or more additional binding domains.
In certain embodiments, for example, the following items are provided.
(Item 1)
A PD-1 binding polypeptide construct comprising at least one heavy chain only variable domain (PD-1 VHH domain) that specifically binds to PD-1.
(Item 2)
PD comprising at least one heavy chain-only variable domain (PD-1 VHH domain) that specifically binds to PD-1 and one or more additional binding domains that bind targets other than PD-1 -1 binding polypeptide constructs.
(Item 3)
a complementarity determining region 1 (CDR1) wherein said at least one VHH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 268, 272, 273, and 313 and an amino acid sequence set forth in SEQ ID NOS: 278 or 314 and a complementarity determining region 3 (CDR3) comprising the amino acid sequence set forth in SEQ ID NO: 283 or 315. .
(Item 4)
Complementarity Determining Region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 268, 272, 273, and 313; CDR2) and a complementarity determining region 3 (CDR3) comprising a selected amino acid sequence set forth in SEQ ID NO: 283 or 315, at least one heavy chain only variable domain (PD-1 VHH domain) A PD-1 binding construct comprising:
(Item 5)
PD-1 according to any of items 1, 2, 3 or 4, wherein said PD-1 VHH domain that specifically binds PD-1 blocks the interaction between PD-1 and PD-L1. Binding Polypeptide Constructs.
(Item 6)
3. The PD-1 binding polypeptide construct of item 2, wherein said one or more additional binding domains bind to a co-stimulatory molecule.
(Item 7)
3. The PD-1 binding polypeptide construct of item 2, wherein said one or more additional binding domains bind to a T cell surface marker.
(Item 8)
8. The PD-1 binding polypeptide construct of item 7, wherein said T cell surface marker is CD8.
(Item 9)
8. The PD-1 binding polypeptide construct of item 7, wherein said T cell surface marker is CD4.
(Item 10)
3. The PD-1 binding polypeptide construct of item 2, wherein said one or more additional binding domains bind to an immune checkpoint other than PD1.
(Item 11)
3. The PD-1 binding polypeptide construct of item 2, wherein said one or more additional binding domains bind to activated receptors on immune cells.
(Item 12)
3. The PD-1 binding polypeptide construct of item 2, wherein said one or more additional domains bind a tumor-associated antigen (TAA).
(Item 13)
3. The PD-1 binding polypeptide construct of item 2, wherein said one or more additional binding domains bind to a cytokine receptor.
(Item 14)
5. The PD-1 binding polypeptide construct of any of items 1, 2, 3, or 4, wherein said polypeptide comprises an immunoglobulin Fc region.
(Item 15)
said at least one PD-1 VHH domain is a sequence set forth in any of SEQ ID NOs: 251-267, 284, or 312, or at least 85%, 86% with any of SEQ ID NOs: 251-267, 284, or 312 , 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. 5. The PD-1 binding polypeptide construct of any of items 1, 2, 3, or 4, comprising and binding to PD-1.
(Item 16)
said at least one PD-1 VHH domain is CDR1, CDR2, and set forth in SEQ ID NOs: 268, 278, and 283, respectively; SEQ ID NOs: 272, 278, and 283, respectively; or SEQ ID NOs: 273, 278, and 283, respectively; PD-1-binding polypeptide construct according to items 1 or 2, comprising CDR3.
(Item 17)
Complementarity Determining Region 1 (CDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 268, 272, 273, and 313; CDR2) and a complementarity determining region 3 (CDR3) comprising the amino acid sequence set forth in SEQ ID NO:283 or 315. An isolated single domain antibody that binds to PD-1.
(Item 18)
an amino acid sequence set forth in any of SEQ ID NOs: 251-267 or 284, or any of SEQ ID NOs: 251-267, 284, or 312 and at least 85%, 86%, 87%, 88%, 89%, 90%; 18. According to item 17, comprising a sequence of amino acids exhibiting 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity and which binds to PD-1 isolated single domain antibody of
(Item 19)
said sdAb is of amino acid set forth in 19. The isolated single domain antibody of item 18, comprising the sequence.
(Item 20)
Polynucleotide(s) encoding a PD-1 binding polypeptide according to any of items 1-4.
(Item 21)
Polynucleotide(s) encoding a single domain antibody according to any of items 17-19.
(Item 22)
A vector comprising the polynucleotide of item 20 or 21.
(Item 23)
A cell comprising the polynucleotide(s) according to item 20 or 21 or the vector according to item 22.
(Item 24)
A method of producing a polypeptide comprising introducing into a cell the polynucleotide(s) of item 20 or 21 or the vector of item 22 and conditions for producing said polypeptide construct. and culturing said cells under a.
(Item 25)
An engineered immune cell comprising a binding molecule according to any of items 1-4 or a binding molecule comprising a single domain antibody according to any of items 17-19, optionally said binding An engineered immune cell, wherein the molecule is secretable from said cell.
(Item 26)
A pharmaceutical composition comprising the PD-1 binding polypeptide of any of items 1-4, the single domain antibody of any of items 17-19, or the engineered immune cell of item 25.
(Item 27)
A method of stimulating or inducing an immune response in a subject, comprising administering to a subject in need thereof a PD-1 binding polypeptide according to any one of items 1-4, a single agent according to any one of items 17-19, A method comprising administering a single domain antibody, or an engineered immune cell according to item 25, or a pharmaceutical composition according to item 26.
(Item 28)
A method of treating a disease or condition in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the PD-1 binding polypeptide of any of items 1-4, any of items 17-19 A method comprising administering a single domain antibody according to item 25, or an engineered immune cell according to item 25, or a pharmaceutical composition according to item 26.
Claims (27)
a)配列番号268に記載されるアミノ酸配列を含む相補性決定領域1(CDR1);
配列番号278に記載されるアミノ酸配列を含む相補性決定領域2(CDR2);および
配列番号283に記載されるアミノ酸配列を含む相補性決定領域3(CDR3);
b)配列番号272に記載されるアミノ酸配列を含むCDR1;
配列番号278に記載されるアミノ酸配列を含むCDR2;および
配列番号283に記載されるアミノ酸配列を含むCDR3;
c)配列番号273に記載されるアミノ酸配列を含むCDR1;
配列番号278に記載されるアミノ酸配列を含むCDR2;および
配列番号283に記載されるアミノ酸配列を含むCDR3;または
d)配列番号313に記載されるアミノ酸配列を含むCDR1;
配列番号314に記載されるアミノ酸配列を含むCDR2;および
配列番号315に記載されるアミノ酸配列を含むCDR3
を含む、PD-1結合ポリペプチド構築物。 1. A PD-1-binding polypeptide construct comprising at least one heavy chain-only variable domain (PD-1 VHH domain) that specifically binds to PD-1 , wherein said PD-1 VHH domain comprises:
a) a complementarity determining region 1 (CDR1) comprising the amino acid sequence set forth in SEQ ID NO:268;
a complementarity determining region 2 (CDR2) comprising the amino acid sequence set forth in SEQ ID NO: 278; and
complementarity determining region 3 (CDR3) comprising the amino acid sequence set forth in SEQ ID NO: 283;
b) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:272;
a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:278; and
a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:283;
c) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:273;
a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:278; and
a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 283; or
d) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:313;
a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:314; and
CDR3 comprising the amino acid sequence set forth in SEQ ID NO:315
A PD-1 binding polypeptide construct comprising:
配列番号278に記載されるアミノ酸配列を含む相補性決定領域2(CDR2);および
配列番号283に記載されるアミノ酸配列を含む相補性決定領域3(CDR3);
b)配列番号272に記載されるアミノ酸配列を含むCDR1;
配列番号278に記載されるアミノ酸配列を含むCDR2;および
配列番号283に記載されるアミノ酸配列を含むCDR3;
c)配列番号273に記載されるアミノ酸配列を含むCDR1;
配列番号278に記載されるアミノ酸配列を含むCDR2;および
配列番号283に記載されるアミノ酸配列を含むCDR3;または
d)配列番号313に記載されるアミノ酸配列を含むCDR1;
配列番号314に記載されるアミノ酸配列を含むCDR2;および
配列番号315に記載されるアミノ酸配列を含むCDR3
を含む、PD-1に結合する単離された単一ドメイン抗体。 a) a complementarity determining region 1 (CDR1) comprising the amino acid sequence set forth in SEQ ID NO:268;
a complementarity determining region 2 (CDR2) comprising the amino acid sequence set forth in SEQ ID NO: 278; and
complementarity determining region 3 (CDR3) comprising the amino acid sequence set forth in SEQ ID NO: 283;
b) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:272;
a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:278; and
a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:283;
c) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:273;
a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:278; and
a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 283; or
d) a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:313;
a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:314; and
CDR3 comprising the amino acid sequence set forth in SEQ ID NO:315
An isolated single domain antibody that binds to PD-1, comprising:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023222989A JP2024024031A (en) | 2018-10-11 | 2023-12-28 | PD-1 single domain antibodies and therapeutic compositions thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862744615P | 2018-10-11 | 2018-10-11 | |
US62/744,615 | 2018-10-11 | ||
US201962791152P | 2019-01-11 | 2019-01-11 | |
US62/791,152 | 2019-01-11 | ||
PCT/US2019/055929 WO2020077257A1 (en) | 2018-10-11 | 2019-10-11 | Pd-1 single domain antibodies and therapeutic compositions thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023222989A Division JP2024024031A (en) | 2018-10-11 | 2023-12-28 | PD-1 single domain antibodies and therapeutic compositions thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022512653A JP2022512653A (en) | 2022-02-07 |
JPWO2020077257A5 true JPWO2020077257A5 (en) | 2022-10-19 |
JP7453219B2 JP7453219B2 (en) | 2024-03-19 |
Family
ID=70164911
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021519705A Active JP7453219B2 (en) | 2018-10-11 | 2019-10-11 | PD-1 single domain antibodies and therapeutic compositions thereof |
JP2023222989A Pending JP2024024031A (en) | 2018-10-11 | 2023-12-28 | PD-1 single domain antibodies and therapeutic compositions thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023222989A Pending JP2024024031A (en) | 2018-10-11 | 2023-12-28 | PD-1 single domain antibodies and therapeutic compositions thereof |
Country Status (8)
Country | Link |
---|---|
US (2) | US11208485B2 (en) |
EP (1) | EP3864049A1 (en) |
JP (2) | JP7453219B2 (en) |
CN (1) | CN113166262A (en) |
AU (1) | AU2019356573A1 (en) |
CA (1) | CA3115285A1 (en) |
TW (1) | TW202028247A (en) |
WO (1) | WO2020077257A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016219772A1 (en) * | 2015-02-22 | 2017-09-21 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD137 |
US11866507B2 (en) | 2017-04-11 | 2024-01-09 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same |
CN111527109A (en) * | 2017-12-26 | 2020-08-11 | 南京金斯瑞生物科技有限公司 | Fusion protein dimer with antibody Fc region as framework and application thereof |
US11208485B2 (en) | 2018-10-11 | 2021-12-28 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
WO2021155071A1 (en) * | 2020-01-29 | 2021-08-05 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
AU2021266688A1 (en) * | 2020-05-04 | 2022-12-08 | Inhibrx Biosciences, Inc. | Canine PD-1-binding polypeptides and uses thereof |
US20230398150A1 (en) * | 2020-10-16 | 2023-12-14 | Fred Hutchinson Cancer Center | Specific targeting of tumor-infiltrating regulatory t cells (tregs) using icos and il-1r |
CN114685655B (en) * | 2020-12-28 | 2024-04-12 | 浙江纳米抗体技术中心有限公司 | PD-1 binding molecules and uses thereof |
CN114763384B (en) * | 2021-01-14 | 2023-03-17 | 立凌生物制药(苏州)有限公司 | PD-1-targeting single domain antibody and derivative and application thereof |
WO2022156773A1 (en) * | 2021-01-21 | 2022-07-28 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd | Protein complexes targeting il12 pathway |
CN115558029B (en) * | 2021-10-22 | 2024-01-30 | 立凌生物制药(苏州)有限公司 | Bispecific antibody targeting PD-1, preparation and application thereof |
WO2023102096A1 (en) * | 2021-12-03 | 2023-06-08 | Merck Sharp & Dohme Llc | Blocking and non-blocking single domain antibodies and uses thereof |
WO2023220643A2 (en) * | 2022-05-10 | 2023-11-16 | Actinium Pharmaceuticals, Inc. | Grp78 nanobodies |
WO2024017281A1 (en) * | 2022-07-20 | 2024-01-25 | 明慧医药(杭州)有限公司 | Multispecific antibody and use thereof |
WO2024028386A1 (en) * | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
WO2024059677A2 (en) * | 2022-09-14 | 2024-03-21 | Ibio, Inc. | Pd-1 agonist antibodies |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3414831A1 (en) | 1984-04-19 | 1985-10-31 | Hoechst Ag, 6230 Frankfurt | PRODUCTION OF POLYPEPTIDES WITH HUMAN GAMMA INTERFERON ACTIVITY |
DE3536939A1 (en) | 1985-10-17 | 1987-04-23 | Hoechst Ag | BIOLOGICALLY ACTIVE DERIVATIVES OF HUMAN (GAMMA) INTERFERON, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING SUCH DERIVATIVES |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
DE4036856C1 (en) | 1990-11-19 | 1992-05-27 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De | |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
DK0590058T3 (en) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humanized heregulin antibody |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5770191A (en) | 1995-05-24 | 1998-06-23 | University Of Florida | Active C-terminal peptides of interferon--gamma and their use |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
JP4460155B2 (en) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | Humanization of mouse antibodies |
GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
EP1002861A1 (en) | 1998-10-26 | 2000-05-24 | Unilever Plc | Antigen-binding proteins comprising a linker which confers restricted conformational flexibility |
US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
FR2822845B1 (en) | 2001-03-30 | 2003-12-12 | Genodyssee | NOVEL POLYNUCLEOTIDES COMPRISING FUNCTIONAL SNP-LIKE POLYMORPHISMS IN THE NUCLEOTIDE SEQUENCE OF THE IFN-ALPHA-21 GENE AS WELL AS NEW POLYPEPTIDES ENCODED BY THESE POLYNUCLEOTIDES AND THEIR THERAPEUTIC USES |
FR2823763A1 (en) | 2001-04-18 | 2002-10-25 | Genodyssee | New polynucleotides and polypeptides of interferon alpha-6 gene comprising at least one single nucleotide polymorphism, useful for preventing or treating e.g. cancer, asthma, allergies, psoriasis, AIDS or Parkinson's disease |
FR2823764B1 (en) | 2001-04-24 | 2003-12-12 | Genodyssee | NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFN ALPHA-17 GENE |
FR2824333B1 (en) | 2001-05-03 | 2003-08-08 | Genodyssee | NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES OF IFN ALPHA 5 |
FR2825102B1 (en) | 2001-05-23 | 2003-08-29 | Genodyssee | NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES OF INTERFERON ALPHA 14 |
FR2825716B1 (en) | 2001-06-11 | 2004-09-24 | Genodyssee | NOVEL POLYNUCLEOTIDES AND POLYPEPTIDES FROM IFN ALPHA 7 |
US7647184B2 (en) | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
AU2003267700A1 (en) | 2002-09-09 | 2004-03-29 | Nautilus Biotech | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
DE60332358D1 (en) | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | PROTEASE-RESISTANT MODIFIED INTERFERON ALPHA POLYPEPTIDE |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
JP3803790B2 (en) | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | Novel diabody-type bispecific antibody |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
WO2005040220A1 (en) | 2003-10-16 | 2005-05-06 | Micromet Ag | Multispecific deimmunized cd3-binders |
CA2541651C (en) | 2003-10-22 | 2011-05-24 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
ME01775B (en) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antibodies with increased fc receptor binding affinity and effector function |
BRPI0417107A (en) | 2003-12-19 | 2007-02-06 | Genentech Inc | antibody fragment, antibody fragment preparation methods, isolated nucleic acid, compositions, host cell, and antibody fragment manufacture and generation methods |
ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
PT1737891E (en) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anti-p-selectin antibodies |
BRPI0511782B8 (en) | 2004-06-03 | 2021-05-25 | Novimmune Sa | anti-cd3 antibodies, use and method of production thereof, pharmaceutical composition, isolated nucleic acid molecule and vector |
US20060024272A1 (en) | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
JP5238936B2 (en) | 2005-03-25 | 2013-07-17 | ジーアイティーアール,インク. | GITR binding molecules and uses thereof |
AU2006244497B2 (en) | 2005-05-06 | 2011-09-22 | Providence Health & Services - Oregon | Trimeric OX40L-immunoglobulin fusion protein and methods of use |
GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
EA014025B1 (en) | 2005-09-12 | 2010-08-30 | Новиммун С.А. | Anti-cd-3 antibody formulations |
EP1994055B1 (en) | 2006-03-10 | 2014-07-02 | Wyeth LLC | Anti-5t4 antibodies and uses thereof |
US8907065B2 (en) | 2006-12-15 | 2014-12-09 | Ablynx N.V. | Polypeptides that modulate the interaction between cells of the immune system |
SI2155783T1 (en) | 2007-04-03 | 2013-10-30 | Amgen Research (Munich) Gmbh | Cross-species-specific cd3-epsilon binding domain |
WO2009025846A2 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
WO2009067800A1 (en) | 2007-11-27 | 2009-06-04 | Viventia Biotech Inc. | Antibodies against a cancer-associated epitope of variant nfkbib and uses thereof |
JP6157046B2 (en) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | Method for generating antibody Fc heterodimer molecules using electrostatic steering effect |
US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
WO2010081173A2 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
AU2010215761B2 (en) | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
KR20120027055A (en) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | Readily isolated bispecific antibodies with native immunoglobulin format |
US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
CN103154034B (en) | 2010-04-13 | 2016-06-08 | 塞尔德克斯医疗公司 | In conjunction with antibody of people CD27 and uses thereof |
WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
ME02678B (en) | 2010-08-23 | 2017-06-20 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
EP2614082B1 (en) | 2010-09-09 | 2018-10-03 | Pfizer Inc | 4-1bb binding molecules |
JP6167040B2 (en) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Design of stable heterodimeric antibodies with mutations in the Fc domain |
US20130078250A1 (en) | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
US20150239991A1 (en) | 2012-09-25 | 2015-08-27 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
AU2013337578C1 (en) | 2012-11-02 | 2018-04-12 | Zymeworks Inc. | Crystal structures of heterodimeric Fc domains |
EP2927321B1 (en) | 2012-11-27 | 2021-02-17 | Ajou University Industry-Academic Cooperation Foundation | Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof |
WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
EP2935589A1 (en) | 2012-12-18 | 2015-10-28 | Novartis AG | Compositions and methods that utilize a peptide tag that binds to hyaluronan |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
CN105051069B (en) | 2013-01-14 | 2019-12-10 | Xencor股份有限公司 | Novel heterodimeric proteins |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
WO2014194100A1 (en) | 2013-05-29 | 2014-12-04 | The Regents Of The University Of California | Anti-cspg4 fusions with interferon for the treatment of malignancy |
ME03675B (en) | 2013-07-05 | 2020-10-20 | Genmab As | Humanized or chimeric cd3 antibodies |
DK3024851T3 (en) | 2013-07-25 | 2018-08-06 | Cytomx Therapeutics Inc | MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT |
TW201605896A (en) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | GITR antigen binding proteins |
NZ718283A (en) | 2013-09-25 | 2022-05-27 | Cytomx Therapeutics Inc | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
LT3736292T (en) | 2013-12-17 | 2024-07-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
CN106029697B (en) | 2013-12-20 | 2021-06-04 | 英特维特国际股份有限公司 | Canine antibodies with modified CH2-CH3 sequences |
AU2015210862B2 (en) | 2014-01-31 | 2020-04-23 | Cytomx Therapeutics, Inc | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
MX2016012779A (en) | 2014-03-31 | 2017-04-27 | Genentech Inc | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists. |
EP3130287B1 (en) | 2014-04-09 | 2022-05-11 | Bando Chemical Industries, Ltd. | Sensor device |
AU2015292406B2 (en) | 2014-07-25 | 2021-03-11 | Cytomx Therapeutics, Inc | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same |
JP6904902B2 (en) | 2014-12-05 | 2021-07-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Domain exchange antibody |
MA41374A (en) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF |
AU2016209247B2 (en) | 2015-01-21 | 2021-02-25 | Inhibrx Biosciences, Inc. | Non-immunogenic single domain antibodies |
AU2016219772A1 (en) | 2015-02-22 | 2017-09-21 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD137 |
CN114573680A (en) | 2015-05-04 | 2022-06-03 | 皮里斯制药有限公司 | CD 137-specific proteins |
EP3292152A1 (en) | 2015-05-07 | 2018-03-14 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
WO2016200672A1 (en) | 2015-06-08 | 2016-12-15 | Cutanea Life Sciences, Inc. | Therapeutic composition |
JP2018526972A (en) | 2015-06-16 | 2018-09-20 | ジェネンテック, インコーポレイテッド | Anti-CD3 antibody and method of use |
WO2017015623A2 (en) | 2015-07-23 | 2017-01-26 | Inhibrx Lp | Multivalent and multispecific gitr-binding fusion proteins |
TWI793062B (en) | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
CR20180105A (en) | 2015-08-17 | 2018-06-12 | Macrogenics Inc | BIO-SPECIFIC MONOVALENT DIACUMS THAT ARE ABLE TO JOIN B7-H3 AND CD3, AND USES OF THE SAME |
EP3344656A1 (en) * | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
TWI783914B (en) | 2015-09-23 | 2022-11-21 | 美商再生元醫藥公司 | Optimized anti-cd3 bispecific antibodies and uses thereof |
EP3377526A1 (en) * | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme Corp. | PD1/CTLA4 Binders |
WO2017118675A1 (en) * | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
MX2018008310A (en) | 2016-01-11 | 2019-01-28 | Inhibrx Inc | Multivalent and multispecific ox40-binding fusion proteins. |
SG10201912405TA (en) | 2016-01-11 | 2020-02-27 | Inhibrx Inc | Multivalent and multispecific 41bb-binding fusion proteins |
EP3411407B1 (en) | 2016-02-05 | 2024-04-03 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
GB201602156D0 (en) | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
EP3231813A1 (en) | 2016-03-29 | 2017-10-18 | F. Hoffmann-La Roche AG | Trimeric costimulatory tnf family ligand-containing antigen binding molecules |
BR112018073739A2 (en) | 2016-05-20 | 2019-02-26 | Harpoon Therapeutics, Inc. | single domain serum albumin binding protein |
WO2018027025A1 (en) | 2016-08-03 | 2018-02-08 | Oncomed Pharmaceuticals, Inc. | Cd40-binding agents and uses thereof |
CN107814845B (en) | 2016-09-14 | 2021-02-09 | 浙江特瑞思药业股份有限公司 | Novel anti-PD-1 nano antibody and application thereof |
IT201600131691A1 (en) * | 2016-12-28 | 2018-06-28 | Ntc Srl | OCULAR TABLET AND METHOD TO WARM A PERIOCULAR REGION. |
CN110167966A (en) | 2017-01-06 | 2019-08-23 | 克雷森多生物制剂有限公司 | The single domain antibody of apoptosis (PD-1) |
CN107474135B (en) | 2017-02-17 | 2020-08-18 | 广西医科大学 | anti-PD-1 nano antibody PD-1/Nb20 and preparation method and application thereof |
EP3732199A1 (en) | 2017-12-27 | 2020-11-04 | TeneoBio, Inc. | Cd3-delta/epsilon heterodimer specific antibodies |
CN108285485B (en) | 2018-01-08 | 2021-02-02 | 乌鲁木齐恒康致远生物技术有限公司 | anti-PD-1 single-domain antibody and application thereof |
US11208485B2 (en) | 2018-10-11 | 2021-12-28 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
-
2019
- 2019-10-11 US US16/600,298 patent/US11208485B2/en active Active
- 2019-10-11 CN CN201980082154.0A patent/CN113166262A/en active Pending
- 2019-10-11 EP EP19797897.6A patent/EP3864049A1/en active Pending
- 2019-10-11 WO PCT/US2019/055929 patent/WO2020077257A1/en unknown
- 2019-10-11 AU AU2019356573A patent/AU2019356573A1/en active Pending
- 2019-10-11 JP JP2021519705A patent/JP7453219B2/en active Active
- 2019-10-11 CA CA3115285A patent/CA3115285A1/en active Pending
- 2019-10-14 TW TW108136936A patent/TW202028247A/en unknown
-
2021
- 2021-11-11 US US17/524,016 patent/US11945869B2/en active Active
-
2023
- 2023-12-28 JP JP2023222989A patent/JP2024024031A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2020077257A5 (en) | ||
WO2017198212A1 (en) | Single domain antibody for ctla4 and derived protein thereof | |
JP2019525771A5 (en) | ||
JP2019524693A5 (en) | ||
WO2017063162A1 (en) | Anti-ox40 antibody and application thereof | |
JP6681433B2 (en) | P2X7 receptor antagonists and agonists | |
JP2019515646A5 (en) | ||
JP2018533371A5 (en) | ||
JP2020531043A (en) | Anti-4-1BB antibody and its preparation and usage | |
JP2018502050A5 (en) | ||
CA2706425A1 (en) | Method for obtaining polypeptide constructs comprising two or more single domain antibodies | |
JP2001521496A (en) | Multivalent and multispecific reagents with high binding activity | |
JP2020500510A5 (en) | ||
RU2018104703A (en) | TUMOR-SPECIFIC ANTIBODY AGAINST EGFR AND ITS APPLICATION | |
JPWO2019129221A5 (en) | ||
TW201734037A (en) | Multi-specific molecules | |
JP2002508924A (en) | A novel method for identifying binding site domains that retain the ability to bind to an epitope | |
JP2024023228A5 (en) | ||
US20230167185A1 (en) | Cd40 binding protein | |
JP2018522888A5 (en) | ||
CN114072427B (en) | Anti-DLL 3 chimeric antigen receptor and uses thereof | |
JP5818003B2 (en) | High-functional variant of humanized anti-EGFR antibody variable region | |
JPWO2020076970A5 (en) | ||
JP2024001073A5 (en) | ||
JP2009278927A (en) | Antibody fragment imitating t-cell receptor and method for producing the same |